(Q37142444)

18 August 2017

Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up (English)

1 reference

18 August 2017

1 reference

1 reference

Ciro Costagliola

1

1 reference

18 August 2017

Ugo Cipollone

2

1 reference

18 August 2017

Michele Rinaldi

3

1 reference

18 August 2017

Michele della Corte

4

1 reference

18 August 2017

Francesco Semeraro

5

1 reference

18 August 2017

Mario R Romano

6

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 November 2008

1 reference

British Journal of Clinical Pharmacology

18 August 2017

1 reference

18 August 2017

66

1 reference

18 August 2017

5

1 reference

18 August 2017

667-673

1 reference

Bevacizumab in glaucoma: a review

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661982

Role of intravitreal bevacizumab in neovascular glaucoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661982

Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661982

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661982

Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661982

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661982

Intravitreal bevacizumab for neovascular glaucoma following central retinal artery occlusion

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661982

Bevacizumab for neovascular ocular diseases

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661982

Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661982

Intravitreal bevacizumab in a patient with neovascular glaucoma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661982

Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661982

Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661982

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661982

Vascular endothelial growth factor: basic science and clinical progress

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661982

A prospective follow-up study of panretinal photocoagulation in preventing neovascular glaucoma following ischaemic central retinal vein occlusion

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661982

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661982

Bevacizumab (Avastin) for the treatment of neovascular glaucoma.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661982

Intravitreal bevacizumab for filtering surgery

3 September 2018

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma

1 reference

12 December 2020

The use of intravitreal bevacizumab in neovascular glaucoma: a case report

1 reference

12 December 2020

Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells

1 reference

12 December 2020

Retinal neovascularization after retinal vaso-obliteration Frequency ? origin ? morphology

1 reference

12 December 2020

Rubeosis iridis: preoperative iris fluorescein angiography and periocular steroids

1 reference

12 December 2020

Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma

1 reference

12 December 2020

Aqueous vascular endothelial growth factor increases in anterior segment ischemia in rabbits

1 reference

12 December 2020

Intracameral bevacizumab for iris rubeosis

1 reference

12 December 2020

Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma

1 reference

12 December 2020

Regression of neovascular iris vessels by intravitreal injection of bevacizumab

1 reference

12 December 2020

[Early effects of systemic and intravitreal bevacizumab (avastin) therapy for neovascular age-related macular degeneration]

1 reference

12 December 2020

10.1111/J.1365-2125.2008.03278.X

Identifiers

DOI

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

19032174

1 reference